chr7-117530974-C-G

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong

The NM_000492.4(CFTR):​c.349C>G​(p.Arg117Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000527 in 1,613,576 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R117C) has been classified as Pathogenic.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000055 ( 0 hom. )

Consequence

CFTR
NM_000492.4 missense

Scores

10
7
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:9U:1

Conservation

PhyloP100: 3.82
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PM1
In a topological_domain Extracellular (size 23) in uniprot entity CFTR_HUMAN there are 19 pathogenic changes around while only 0 benign (100%) in NM_000492.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr7-117530974-C-T is described in Lovd as [Pathogenic].
PP3
MetaRNN computational evidence supports a deleterious effect, 0.984
PP5
Variant 7-117530974-C-G is Pathogenic according to our data. Variant chr7-117530974-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 53762.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-117530974-C-G is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CFTRNM_000492.4 linkc.349C>G p.Arg117Gly missense_variant Exon 4 of 27 ENST00000003084.11 NP_000483.3 P13569-1A0A024R730

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CFTRENST00000003084.11 linkc.349C>G p.Arg117Gly missense_variant Exon 4 of 27 1 NM_000492.4 ENSP00000003084.6 P13569-1

Frequencies

GnomAD3 genomes
AF:
0.0000329
AC:
5
AN:
152174
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000588
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000199
AC:
5
AN:
250944
Hom.:
0
AF XY:
0.0000295
AC XY:
4
AN XY:
135604
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000352
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000547
AC:
80
AN:
1461402
Hom.:
0
Cov.:
31
AF XY:
0.0000426
AC XY:
31
AN XY:
726990
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000693
Gnomad4 OTH exome
AF:
0.0000331
GnomAD4 genome
AF:
0.0000329
AC:
5
AN:
152174
Hom.:
0
Cov.:
32
AF XY:
0.0000135
AC XY:
1
AN XY:
74330
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000588
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.00000534
Hom.:
0
Bravo
AF:
0.0000227
ExAC
AF:
0.0000165
AC:
2
EpiCase
AF:
0.0000545
EpiControl
AF:
0.000178

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:5Uncertain:1
Jan 04, 2022
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.R117G pathogenic mutation (also known as c.349C>G), located in coding exon 4 of the CFTR gene, results from a C to G substitution at nucleotide position 349. The arginine at codon 117 is replaced by glycine, an amino acid with dissimilar properties. The mutation has been reported as a variant of varying clinical consequences (VVCC) (Sosnay PR et al. Pediatr. Clin. North Am., 2016 08;63:585-98; The Clinical and Functional TRanslation of CFTR (CFTR2); available at http://cftr2.org. Accessed November 14, 2018). It has been described in the heterozygous state in a male with congenital bilateral absence of the vas deferens (CBAVD); a second CFTR alteration was not observed (Claustres M et al. Hum. Mutat., 2000;16:143-56; Daudin M et al. Fertil. Steril., 2000 Dec;74:1164-74). In addition, this mutation was observed in conjunction with p.N34S in the SPINK1 gene in an individual with idiopathic pancreatitis (Masson E et al. PLoS ONE. 2013; 8(8):e73522). In an in vitro study, the R117G protein had 35% of normal CFTR function (Raraigh KS et al. Am. J. Hum. Genet., 2018 Jun;102:1062-1077). Based on internal structural analysis, this variant is more disruptive than known pathogenic variants at the same position and in the same region (Liu F et al. Cell, 2017 03;169:85-95.e8). Furthermore, there are also multiple pathogenic alterations at this same position, including p.R117H and p.R117C (Thauvin-Robinet C et al. J. Med. Genet., 2013 Apr;50:220-7; Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). Based on available evidence to date, this variant has not been reported as causative of classic CF; however, it may contribute to the development of a CFTR-related disorder and is thus classified as as a disease-causing mutation. -

Aug 17, 2019
Johns Hopkins Genomics, Johns Hopkins University
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Previously reported disease-causing CFTR variant associated with varying clinical consequences. See www.CFTR2.org for phenotype information. -

Jul 22, 2021
Genome-Nilou Lab
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Dec 11, 2024
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: CFTR c.349C>G (p.Arg117Gly) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 250944 control chromosomes. c.349C>G has been reported been reported in the CFTR2 database in affected individuals and has been described as having variable clinical consequences. It has been reported in the literature in multiple compound heterozygous individuals affected with Cystic Fibrosis (Desai_2018, McCague_2019) as well as in individuals with pancreatitis (e.g., Masson_2013) and congenital bilateral absence of the vas deferens (e.g., Daudin_2000). These data indicate that the variant is very likely to be associated with disease. Att least two publications report experimental evidence evaluating an impact on protein function (e.g. Raraigh_2018, Bihler_2024). The most pronounced variant effect resulted in approximately 23% of normal chloride channel conductance relative to wild type (Bihler_2024). Additionally, different variants affecting the same codon have been classified as pathogenic by our lab (c.349C>T, p.Arg117Cys and c.350G>A, p.Arg117His), supporting the critical relevance of codon 117 to CFTR protein function. The following publications have been ascertained in the context of this evaluation (PMID: 11119745, 29944384, 33922413, 20706124, 23951356, 30888834, 29805046, 38388235). ClinVar contains an entry for this variant (Variation ID: 53762). Based on the evidence outlined above, the variant was classified as pathogenic. -

Sep 23, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 117 of the CFTR protein (p.Arg117Gly). This variant is present in population databases (rs77834169, gnomAD 0.004%). This missense change has been observed in individuals with clinical symptoms of CFTR-related conditions (PMID: 11119745, 29805046, 29944384, 30888834). ClinVar contains an entry for this variant (Variation ID: 53762). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CFTR function (PMID: 29805046). This variant disrupts the p.Arg117 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7525450, 7529962, 11788090, 15482777, 21520337, 21783433, 22658665, 23974870, 24586523). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -

Nov 08, 2017
Counsyl
Significance: Uncertain significance
Review Status: flagged submission
Collection Method: clinical testing

- -

not provided Pathogenic:2
Jun 26, 2024
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The CFTR c.349C>G (p.Arg117Gly) variant has been reported as a variant of varying clinical consequences (VVCC) (PMID: 36409994 (2022) and CFTR2 (https://cftr2.org/)). This variant has been observed in individuals with clinical symptoms of CFTR-related conditions (PMIDs: 29944384 (2018)) and 30888834 (2019)) including individuals with pancreatitis (PMIDs: 18687795 (2008) and 23951356 (2013)) and congenital bilateral absence of the vas deferens (PMIDs: 11119745 (2000) and 10923036 (2000)). Experimental studies have indicated that the variant has reduced CFTR activity compared to the wild type CFTR, however the effect is still inconclusive (PMIDs: 29805046 (2018), 30888834 (2019), and 38388235 (2024)). In addition, other pathogenic variants have been reported at the same positions, including p.R117H and p.R117C (PMIDs: 19880712 (2009) and 23974870 (2013)). The frequency of this variant in the general population, 0.000039 (5/128904 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. ClinVar contains an entry for this variant (URL: www.ncbi.nlm.nih.gov/clinvar, Variation ID: 53762). Based on the available information, this variant is classified as likely pathogenic. -

Aug 10, 2019
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The CFTR c.349C>G; p.Arg117Gly variant (rs77834169) has been described in individuals with cystic fibrosis (CF) when found in trans to another CF-causing variant, but has also been described in association with other CFTR-related disorders such as congenital bilateral absence of vas deferens or pancreatitis in individuals that do not have CF (see link to CFTR2 database, Daudin 2000, Masson 2013). This variant is reported in ClinVar (Variation ID: 53762) and is found in the general population with an overall allele frequency of 0.002% (6/282344 alleles) in the Genome Aggregation Database. The arginine at residue 117 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.773). Due to this variant having a variable presentation in affected individuals, it is considered to be pathogenic with varying clinical consequences. References: CFTR2 database: http://www.cftr2.org/ Daudin M et al. Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counseling. 2000;Fertil Steril. 74(6):1164-74. Masson E et al. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in 253 young French patients. 2013;PLoS One. 8(8):e73522. -

CFTR-related disorder Pathogenic:1
Jan 18, 2021
CFTR-France
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Feb 15, 2024
Baylor Genetics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.69
BayesDel_addAF
Pathogenic
0.42
D
BayesDel_noAF
Pathogenic
0.47
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.72
.;D;.;.;T;.
Eigen
Uncertain
0.43
Eigen_PC
Uncertain
0.43
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.89
D;D;D;D;D;D
M_CAP
Pathogenic
0.84
D
MetaRNN
Pathogenic
0.98
D;D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Benign
1.4
.;L;.;.;.;L
PrimateAI
Uncertain
0.52
T
PROVEAN
Pathogenic
-6.9
D;N;.;.;N;.
REVEL
Pathogenic
0.77
Sift
Pathogenic
0.0
D;D;.;.;D;.
Sift4G
Pathogenic
0.0
D;D;.;.;D;.
Polyphen
1.0
.;D;.;.;.;.
Vest4
0.96
MutPred
0.91
.;Loss of ubiquitination at K114 (P = 0.0709);Loss of ubiquitination at K114 (P = 0.0709);Loss of ubiquitination at K114 (P = 0.0709);Loss of ubiquitination at K114 (P = 0.0709);Loss of ubiquitination at K114 (P = 0.0709);
MVP
0.99
MPC
0.0098
ClinPred
0.89
D
GERP RS
5.7
Varity_R
0.79
gMVP
0.95

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs77834169; hg19: chr7-117171028; API